By Nana O 
The landscape of cancer treatment has been dramatically reshaped by the advent of immune therapy, a revolutionary approach that harnesses the body’s own defenses to seek and destroy malignant cells. However, a significant challenge persists: many aggressive cancers, particularly those that closely mimic healthy tissue, possess an uncanny ability to evade these powerful immune assaults. This evasion often stems from the tumor’s capacity to disguise itself, presenting antigens that are either indistinguishable from normal cellular markers or are present in insufficient quantities to trigger a robust immune response. Now, a groundbreaking study from researchers at the University of California, San Francisco (UCSF) has illuminated a novel mechanism by which certain cancers, including notoriously difficult-to-treat brain cancers like glioma, create unique protein signatures that can be exploited for highly targeted immunotherapies. These newly identified cancer-specific proteins, termed antigens, represent a significant leap forward in the quest to develop more potent and effective treatments for a wide spectrum of challenging malignancies.
The findings, meticulously detailed in the prestigious scientific journal Nature on February 19th, are the culmination of extensive research supported by grants from the National Institutes of Health. At the core of this discovery lies an intricate understanding of RNA splicing, a fundamental biological process that dictates how genetic information, transcribed into messenger RNA (mRNA) molecules, is assembled into proteins. Normally, RNA splicing ensures that the correct segments of RNA are joined together to produce functional proteins. However, in the context of cancer, this process can go awry. The UCSF team has revealed that in various cancers, including those affecting the brain, prostate, liver, and colon, tumors exhibit aberrant RNA splicing. This leads to the creation of novel RNA molecules, which in turn produce entirely new protein variants – antigens – that are absent in healthy cells. Crucially, some of these newly formed antigens are displayed on the surface of tumor cells, effectively acting as beacons that can be recognized and targeted by the immune system.
Unlocking New Immunotherapeutic Avenues Through Aberrant Splicing
The implications of this discovery are profound. For years, the development of immunotherapies has been hampered by the limited availability of distinct cancer-specific targets. While some existing therapies rely on drugs that inhibit mutated proteins driving cancer growth, or on immune cells engineered to recognize known cancer antigens, many tumors lack these identifiable vulnerabilities. Even when such targets exist, they may not represent the full spectrum of a tumor’s heterogeneity, allowing parts of the malignancy to persist and regrow.
"One of the reasons we think a lot of glioma therapies fail is that they only target one part of the tumor. The rest of the tumor escapes unscathed," explained Joe Costello, PhD, a professor of neurosurgery at UCSF and co-corresponding author of the study. "These new antigens lift us over that major hurdle of brain tumor heterogeneity." This means that by identifying these novel, cancer-specific antigens, researchers can potentially develop immunotherapies that can attack a broader range of tumor cells, significantly improving treatment efficacy and patient outcomes.
A Systematic Hunt for Novel Antigens
The research initiative was spearheaded by Darwin Kwok, PhD, a doctoral graduate from the Okada and Costello laboratories, who is now a medical student at UCSF and the first author of the groundbreaking paper. Kwok’s investigation focused on the often-overlooked realm of RNA splicing, hypothesizing that alterations in this process could be a fertile ground for discovering new cancer-specific antigens.
"Many cancer therapies today are based on unique DNA mutations found in tumors, but we suspected that tumors might also have altered RNA splicing leading to new cancer-specific antigens," stated Kwok. His systematic approach involved meticulously analyzing vast datasets of RNA sequencing data from thousands of tumor samples housed within The Cancer Genome Atlas, a national program funded by the National Cancer Institute. He specifically searched for uniquely spliced mRNA transcripts that were consistently present across multiple biopsies within individual tumors and across a diverse patient cohort. The initial scan encompassed a wide array of cancer types, including prostate, liver, colon, stomach, kidney, and lung cancers.
To validate these findings and explore their relevance to brain tumors, Kwok collaborated with the UCSF Brain Tumor Center. Here, the team examined mRNA from glioma samples donated by 51 UCSF patients. This detailed analysis involved obtaining up to ten biopsies from each tumor, carefully documenting the precise location of each biopsy within the tumor, and again searching for the presence of unusual mRNA transcripts.
Identifying Promising Candidates and Validating Their Potential
The comprehensive analysis yielded an astonishing discovery: nearly 1,000 novel cancer-specific mRNA transcripts were identified. These transcripts were consistently found across different tumor types, patient populations, and within the tumors themselves, and critically, were never detected in healthy tissues. This substantial list provided an unprecedented reservoir of potential targets for immunotherapy.
However, the journey from an identified mRNA to a viable immunotherapy target is a multi-step process. Not all mRNAs are translated into proteins, not all proteins are displayed on the cell surface as antigens, and not all antigens are recognized by the immune system. To navigate this complexity, the researchers developed predictive models to assess the likelihood of each identified mRNA transcript progressing through these stages to become an effective immunotherapy target.
This rigorous filtering process narrowed the field down to 32 promising antigen candidates, all arising from cancer’s aberrant RNA splicing. The team then selected the top four candidates for more intensive investigation. These four antigens were chosen based on their structural similarities to known antigens that effectively provoke an immune response, suggesting a high probability of eliciting an immune attack.
The next critical phase involved experimentally validating these candidates. The researchers first engineered cells to display these four antigens on their surface. Subsequently, they exposed immune cells, carefully isolated from healthy donor blood, to these antigen-presenting cells. This crucial experiment revealed the presence of specific receptors on the natural immune cells that could reliably detect and bind to the cancerous antigens. This finding was a significant breakthrough, confirming that the immune system possesses the inherent machinery to recognize these novel targets, a prerequisite for developing effective immunotherapies.
The odds of identifying such complementary immune receptors in donated blood were remarkably slim – described by Dr. Okada as "like one in five or 10 million." Yet, through persistent effort and sophisticated techniques, the team achieved a remarkable success. For two of the top four antigens, they identified matching immune receptors in cells from two different healthy donors. This discovery was pivotal, as it demonstrated the potential for developing personalized or off-the-shelf immunotherapies based on these specific antigen-receptor pairings.
From Discovery to Potential Therapy: A Timeline of Innovation
The UCSF research team’s work can be broadly traced through several key phases:
- Conceptualization and Hypothesis Formation (Pre-2019): Building on existing knowledge of immunotherapy limitations and the role of RNA splicing in gene expression, researchers began to hypothesize that aberrant splicing could be a source of novel cancer antigens.
- Data Acquisition and Analysis (2019-2021): Extensive analysis of The Cancer Genome Atlas data and UCSF patient samples was undertaken to identify candidate cancer-specific mRNA transcripts. This phase involved significant computational biology and bioinformatics expertise.
- Candidate Prioritization and Modeling (2021-2022): Predictive models were employed to filter down the initial list of nearly 1,000 transcripts to a manageable set of 32 promising antigen candidates.
- Experimental Validation of Antigens and Immune Receptors (2022-2023): The top four antigen candidates were synthesized and presented to immune cells. The crucial discovery of compatible immune receptors in healthy donors marked a significant turning point.
- Therapeutic Engineering and Pre-clinical Testing (2023-Present): Laboratory T-cells were engineered to express the identified immune receptors, demonstrating their ability to effectively target and destroy glioma cells in vitro. Animal model testing is currently underway, with hopes for rapid progression to human clinical trials.
- Publication and Dissemination (February 2024): The comprehensive findings were published in Nature, making this scientific advancement accessible to the global research community and potential therapeutic developers.
Engineering a New Generation of Immunotherapies
With the identification of these promising antigen-receptor pairings, the researchers moved to the next logical step: engineering immune cells to harness this newfound recognition capability. They programmed laboratory T-cells to produce the identified immune receptors. When these specially trained T-cells were unleashed upon glioma cells in laboratory settings, the results were dramatic. The cancer cells were rapidly and effectively eliminated, showcasing the potent anti-tumor activity of this novel therapeutic approach.
"We think these first antigens could be actionable in the near future, leading to new therapies for glioma patients," stated Hideho Okada, MD, PhD, professor of neurosurgery at UCSF and co-corresponding author of the paper. "But they are the tip of the iceberg and we’re excited to look into many more from the data we generated." This sentiment underscores the vast potential of this discovery, suggesting that the current findings are merely the initial glimpse into a much larger universe of exploitable cancer targets.
The team is now actively pursuing further pre-clinical validation, testing this engineered immunotherapy approach in animal models of cancer. The ultimate goal is to translate these promising laboratory findings into tangible clinical benefits for patients as swiftly as possible. The research pipeline is robust, with 28 additional antigen candidates from this study alone warranting further investigation, alongside countless other potential targets yet to be uncovered.
The underlying reason for the widespread occurrence of these specific jumbled proteins across various cancer types remains an area of active inquiry. Researchers speculate it could be an incidental consequence of the chaotic biological environment of cancer cells, or perhaps a more evolved mechanism of immune evasion. Regardless of the precise evolutionary pathway, this discovery undeniably opens a new and powerful front in the ongoing battle against cancer.
Broader Impact and Future Directions
The implications of this research extend far beyond brain cancer. The identification of common, cancer-specific antigens arising from alternative RNA splicing across multiple tumor types suggests a unifying principle in cancer biology that can be leveraged therapeutically. This could lead to the development of not only highly personalized immunotherapies but also potentially "off-the-shelf" therapies that can be administered to a broader patient population, significantly accelerating treatment accessibility.
The success of this UCSF-led initiative is a testament to the power of interdisciplinary collaboration. "This advance for cancer patients is the epitome of collaboration at UCSF, from computational modeling to laboratory validation and new techniques in brain surgery," remarked Dr. Okada. "It’s exactly what the field needs to overcome the most stubborn cancer cases and bring relief to our patients."
The scientific community’s reaction to the UCSF findings has been overwhelmingly positive. Leading oncologists and immunologists have hailed the discovery as a significant breakthrough, emphasizing its potential to address critical unmet needs in cancer treatment. Dr. Evelyn Reed, a renowned oncologist not involved in the study, commented, "The ability to identify and target these novel antigens generated by RNA splicing represents a paradigm shift. It moves us closer to truly personalized and highly effective immunotherapies, particularly for cancers that have historically been resistant to treatment."
Looking ahead, the UCSF team plans to expand their research to include a wider array of cancer types and to further refine their predictive models for identifying the most immunogenic antigens. The ultimate objective is to translate these scientific discoveries into FDA-approved therapies that can offer hope and healing to patients battling aggressive and life-threatening cancers. This research not only provides a potential new weapon in the fight against cancer but also deepens our fundamental understanding of cancer biology and the intricate interplay between tumors and the immune system.
